National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting, 48546 [2020-17439]
Download as PDF
<![CDATA[
48546
Federal Register / Vol. 85, No. 155 / Tuesday, August 11, 2020 / Notices
comment session or by submitting a
written public comment. Comments
should be pertinent to the meeting
discussion. Persons who wish to
provide verbal or written public
comment should review instructions at
https://www.hhs.gov/oidp/advisorycommittee/blood-tissue-safetyavailability/meetings/2020-08-26/
index.html and respond by midnight
August 19, 2020, ET. Verbal comments
will be limited to three minutes each to
accommodate as many speakers as
possible.
The ACBTSA provides advice to the
Secretary through the Assistant
Secretary for Health. The Committee
advises on a range of policy issues to
include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national survey and data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical, and legal issues related
to the safety of blood, blood products,
and tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee has met regularly since
its establishment in 1997.
Dated: July 22, 2020.
James J. Berger,
Designated Federal Officer, Tick-Borne
Disease Working Group, Office of Infectious
Disease and HIV/AIDS Policy.
[FR Doc. 2020–17508 Filed 8–10–20; 8:45 am]
BILLING CODE 4150–28–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Neurological
Disorders and Stroke; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
VerDate Sep<11>2014
17:02 Aug 10, 2020
Jkt 250001
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Neurological Disorders and Stroke Special
Emphasis Panel; Opportunities for
Collaborative Research at the NIH Clinical
Center (U01 Clinical Trials Optional).
Date: August 14, 2020.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, NSC
Building, 6001 Executive Boulevard,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mirela Milescu, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Activities,
NINDS/NIH, NSC, 6001 Executive Blvd.,
Suite 3208, MSC 9529, Bethesda, MD 20892,
mirela.milescu@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: August 5, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–17439 Filed 8–10–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Co-Clinical
Imaging—Quantitative Methods.
Date: September 17, 2020.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W108, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Clifford W. Schweinfest,
Ph.D., Scientific Review Officer, Special
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
9609 Medical Center Drive, Room 7W108,
Rockville, MD 20850, 240–276–6343,
schweinfestcw@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; Provocative
Question 7.
Date: September 24, 2020.
Time: 11:00 a.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W640, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Saejeong J. Kim, Ph.D.,
Scientific Review Officer, Special Review
Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 9609 Medical
Center Drive, Room 7W640, Rockville, MD
20850, 240–276–7684, saejeong.kim@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel;
Mechanisms of Cancer Drug Resistance.
Date: September 28, 2020.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W246, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Jun Fang, Ph.D., Scientific
Review Officer, Research Technology and
Contract Review Branch, Division of
Extramural Activities, National Cancer
Institute, NIH, 9609 Medical Center Drive,
Room 7W246, Rockville, MD 20850, 240–
276–5460, jfang@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–4: NCI
Clinical and Translational R21 and Omnibus
R03 Review.
Date: October 1–2, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
7W254, Rockville, MD 20850 (Telephone
Conference Call).
Contact Person: Eduardo Emilio Chufan,
Ph.D., Scientific Review Officer, Research
Technology and Contract Review Branch,
Division of Extramural Activities, National
Cancer Institute, NIH, 9609 Medical Center
Drive, Room 7W254, Rockville, MD 20850,
240–276–7975, chufanee@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel; SEP–1:
Research Answers to NCI Provocative
Questions.
Date: October 8, 2020.
Time: 8:00 a.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Room
E:\FR\FM\11AUN1.SGM
11AUN1
]]>Agencies
[Federal Register Volume 85, Number 155 (Tuesday, August 11, 2020)]
[Notices]
[Page 48546]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-17439]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke; Notice
of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Neurological Disorders
and Stroke Special Emphasis Panel; Opportunities for Collaborative
Research at the NIH Clinical Center (U01 Clinical Trials Optional).
Date: August 14, 2020.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, NSC Building, 6001
Executive Boulevard, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mirela Milescu, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural
Activities, NINDS/NIH, NSC, 6001 Executive Blvd., Suite 3208, MSC
9529, Bethesda, MD 20892, [email protected].
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.853,
Clinical Research Related to Neurological Disorders; 93.854,
Biological Basis Research in the Neurosciences, National Institutes
of Health, HHS)
Dated: August 5, 2020.
Miguelina Perez,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-17439 Filed 8-10-20; 8:45 am]
BILLING CODE 4140-01-P
